Reblozyl (luspatercept-aamt)

Product Name:

Reblozyl (luspatercept-aamt)

Categories: Hematology, Oncology

Discover Savings on Your Medication Access

Trusted concierge service, secure process, and real savings for patients in the U.S.

Table of Contents

Reblozyl (luspatercept-aamt)

Product Category

Hematology – Erythroid Maturation Agent / Anemia Therapy

Brand Name

Reblozyl

Generic Name or Biosimilar

No

Active Ingredient

Luspatercept-aamt

Prescription Status

Prescription-only

Targeted Conditions

  • Anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions
  • Anemia in adult patients with myelodysplastic syndromes (MDS) with ring sideroblasts, who failed an erythropoiesis-stimulating agent (ESA)
  • Anemia in adult patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Off-Label Usage

  • Explored in other transfusion-dependent anemias (e.g., Diamond-Blackfan anemia, sickle cell disease – investigational)

(Off-label usage is experimental and should only be considered in clinical trial settings.)

Drug Classification Overview

Reblozyl is an erythroid maturation agent that binds to select transforming growth factor-beta (TGF-β) superfamily ligands to reduce SMAD2/3 signaling.
This enhances late-stage erythropoiesis, increasing red blood cell production in specific hematologic disorders.

Manufacturer in the USA, Mexico, and Canada

USA: Bristol-Myers Squibb Company
Mexico: Bristol-Myers Squibb de México S. de R.L. de C.V.
Canada: Bristol-Myers Squibb Canada

Available Strengths and Dosage Forms – United States, Mexico, and Canada

Country Comparison – United States vs Mexico and Canada

  • Equivalent active ingredient and therapeutic effect across countries
  • Formulation and dosing guidelines are aligned internationally
  • Packaging and language may differ
  • Cold chain shipping is required

Average Retail Price (Monthly Treatment)

Canada: Patients may save approximately 25%–40% vs U.S. retail
Mexico: Patients may save approximately 30%–45% vs U.S. retail

Savings vary based on availability, local regulations, and cold chain requirements.

Where to Buy USA

  • Available only in specialty and hospital pharmacies with oncology/hematology support (CVS Specialty, Walgreens Specialty, Optum, Accredo, hospital infusion centers)

Patients must be monitored by a hematologist/oncologist when receiving Reblozyl.

Storage Requirements

  • Store refrigerated at 2°C–8°C (36°F–46°F)
  • Do not freeze; protect from light
  • Maintain cold chain during shipping and handling

Key Benefits

  • Improves red blood cell production in transfusion-dependent anemias
  • Reduces the need for regular transfusions
  • Offers a targeted treatment option beyond ESAs
  • Shown to improve hemoglobin levels and reduce transfusion burden in clinical trials

Shipping from Canada

This medication is accessed through licensed Canadian pharmacies regulated by Health Canada. MedicalMex facilitates access exclusively through certified specialty pharmacies and hospital-based distribution centers.

MedicalMex facilitates:

  • Prescription verification and coordination with hematology centers
  • Specialized medication handling and logistics
  • Cold chain–compliant shipping
  • Telehealth consultations with hematology specialists if needed
  • Case management and patient support throughout therapy

Buying from Mexico

Reblozyl is available in certified pharmacies and hospital distribution centers regulated by COFEPRIS. MedicalMex coordinates access through hematology clinics and treatment centers.

MedicalMex facilitates:

  • Patient travel support when treatment requires in-person administration
  • Prescription validation with licensed physicians
  • Specialty pharmacy coordination
  • Cold chain handling and monitoring
  • Concierge-level bilingual patient support

Side Effects

  • Common: Fatigue; Headache; Dizziness; Nausea; Diarrhea; Bone pain
  • Moderate: Hypertension; Joint pain; Abdominal pain
  • Serious: Thrombosis/embolism; Severe hypertension; Hypersensitivity reactions

Patients should be monitored for thromboembolic events, hypertension, and allergic reactions during treatment.

Warnings and Precautions

  • Not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia
  • Not recommended in patients under 18 years
  • Pregnancy and breastfeeding: safety not established
  • Monitor hemoglobin levels and blood pressure regularly
  • Discontinue if unacceptable toxicity or lack of response

Alternative Medications (by Indication)

Erythropoiesis-stimulating agents (ESAs): Epoetin alfa, Darbepoetin alfa
Other investigational agents for MDS and beta-thalassemia
Supportive care with transfusions and iron chelation therapy

Medication FAQs

Reblozyl is used to treat anemia in adults with beta-thalassemia, MDS with ring sideroblasts, and MDS/MPN-RS-T who require regular transfusions or failed ESA therapy.

Reblozyl is administered as a subcutaneous injection by a healthcare professional, usually every 3 weeks.

No. It is not a substitute for transfusions in acute settings but helps reduce the long-term need for transfusions.

Fatigue, headache, dizziness, nausea, diarrhea, and bone pain are the most common side effects.

Yes, it is available through licensed specialty pharmacies and treatment centers regulated by Health Canada and COFEPRIS.

No. As of 2025, there is no generic or biosimilar available.

Patients with uncontrolled hypertension or those under 18 years should not take Reblozyl.

Regular blood tests and blood pressure monitoring are required during therapy.

Yes. MedicalMex coordinates with certified pharmacies and hematology clinics in Mexico and Canada to facilitate safe access.

Yes. A valid prescription from a hematologist/oncologist is mandatory in all regions.